Category: Sleep Treatments

Pharmaceuticals

Latest

FDA Accepts NDA for Low-Sodium Alternative to Xyrem for Narcolepsy

The FDA accepted for filing with Priority Review the Jazz Pharmaceuticals plc's NDA seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.